The firm is a U.S.-based venture capital investor focused exclusively on women’s health, with investments spanning life sciences, digital health, and technology-enabled healthcare services. The firm primarily invests at the Seed and Series A stages, typically committing $1M–$3M per investment. The firm can lead or co-lead financing rounds and takes an active approach to portfolio development, often seeking board representation or observer rights. The firm primarily targets U.S.-based companies but also considers international opportunities when investment proceeds support U.S.-focused activities, including regulatory development, clinical validation, or commercialization.

The firm invests in healthcare solutions addressing conditions that exclusively or disproportionately affect women, as well as diseases where female-specific physiology creates opportunities to improve diagnosis, treatment, and clinical outcomes. The firm evaluates opportunities across therapeutics, medical devices, diagnostics, digital health, and technology-enabled healthcare delivery. Investment decisions are guided by four principal considerations: transformative innovation, access to care, affordability, and systemic improvement in healthcare delivery. The firm prioritizes technologies and business models capable of improving patient outcomes, reducing barriers to adoption, and addressing significant gaps in women’s healthcare.

From a company and management team perspective, the firm seeks differentiated healthcare solutions with strong commercial potential and a clear pathway to the U.S. market. The firm places particular emphasis on measurable patient impact, scalability, and the ability to improve healthcare accessibility and affordability. The firm takes an active role in supporting portfolio companies through strategic guidance, governance participation, business development, and commercialization planning.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a U.S.-based life sciences venture development and investment organization focused on supporting early-stage biotechnology and medical technology companies. The firm invests from Pre-Seed through Series A and combines financial investment with laboratory infrastructure, specialized equipment, operational resources, and company-building support. The firm utilizes multiple investment structures, including direct early-stage equity investments and in-kind arrangements that provide access to laboratory facilities and other resources in exchange for equity. The firm primarily operates within major U.S. life sciences innovation ecosystems.

The firm invests exclusively in life sciences, including therapeutics, medical devices, diagnostics, biotechnology platforms, and enabling healthcare technologies. Areas of interest include drug discovery, precision medicine, oncology, cell and gene therapies, advanced diagnostics, medical technologies, and life science tools. The firm prioritizes differentiated scientific innovations with strong translational potential and meaningful clinical applications. The firm is particularly interested in very early-stage technologies emerging from academic institutions, research centers, and healthcare systems that can benefit from dedicated infrastructure and company development support.

From a company and management team perspective, the firm seeks founders and technical teams developing scientifically differentiated technologies with strong commercial potential. The firm places significant emphasis on scientific validation, technical expertise, and the ability to address substantial unmet medical needs. The firm provides hands-on support in company formation, fundraising, operational strategy, talent recruitment, and commercialization planning. The firm also facilitates access to scientific advisors, industry partners, institutional investors, and specialized research infrastructure to accelerate portfolio company development.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a North America-based venture philanthropy investor affiliated with a private foundation dedicated to advancing research and innovation in brain tumors. The firm typically invests from Seed through Series A, with initial investments ranging from $250K–$2M and the potential for follow-on participation. The firm generally seeks to make several new investments annually and prefers to participate alongside other investors rather than lead financing rounds. The firm primarily targets companies located in the United States and Canada.

The firm focuses on technologies addressing brain tumors and related neurological conditions, including therapeutics, medical devices, diagnostics, software, and other healthcare innovations. The firm is open to a broad range of modalities and technologies, provided there is a clear or potential application in brain cancer. The firm may also consider companies initially developing technologies for other indications when the underlying approach could eventually be applied to brain tumors. For therapeutics, the firm generally prefers preclinical and early clinical-stage programs, while diagnostic technologies may be considered at later stages of clinical development.

From a company and management team perspective, the firm seeks founding teams with complementary scientific, technical, and commercial capabilities. Experience in business development, fundraising, or company building is viewed favorably but is not a strict requirement. The firm takes an active approach to supporting portfolio companies and can provide access to specialized scientific expertise, clinical research relationships, and a network of researchers and healthcare professionals.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is the U.S.-based clinical development and research organization of a diversified global pharmaceutical company. The firm is actively seeking global partnering opportunities that complement its parent company’s therapeutic pipeline and long-term research priorities. Potential partnership structures include in-licensing, co-development, co-commercialization, and other strategic collaborations. While the firm has the capacity to make direct investments, its primary focus is on strategic partnerships rather than traditional venture capital investments.

The firm focuses on novel therapeutics addressing cardiovascular disease, metabolic disorders, peripheral arterial disease, and pain management. The firm is generally stage-agnostic and is particularly interested in compounds that can be advanced through clinical proof-of-concept. Although the firm’s historical expertise centers on small molecules, the firm is expanding its interest to include antibodies, cell therapies, and other emerging therapeutic modalities. The firm also has strong interest in innovative platform technologies with potential applications across multiple therapeutic programs.

From a company and management team perspective, the firm does not impose specific requirements regarding organizational structure, management experience, or company maturity. The firm seeks differentiated therapeutic assets and technologies with strong scientific rationale, compelling development potential, and strategic alignment with its broader pharmaceutical research and development capabilities.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a Europe-based venture capital investor specializing exclusively in medical technology. The firm typically invests €5M–€15M per company and manages dedicated investment funds focused on innovative medical devices and related technologies. The firm takes an active investment approach and can lead financing rounds or participate alongside other specialist investors. The firm primarily targets investment opportunities across Europe, Israel, and North America.

The firm focuses on medical technologies addressing significant cardiovascular, neurovascular, and other chronic disease indications. Areas of particular interest include structural heart disease, heart failure, aortic and peripheral vascular disease, stroke, hypertension, and electrophysiology. The firm also selectively evaluates neuromodulation, medical robotics, medical imaging, and patient monitoring technologies, particularly those with applications in cardiovascular and neurovascular care. The firm primarily invests in clinical-stage through commercial-stage medical technologies and does not target pharmaceuticals, biotechnology, healthcare services, or wellness products.

From a company and management team perspective, the firm seeks experienced medical technology entrepreneurs developing differentiated products that address significant unmet clinical needs. The firm takes an active role in supporting portfolio companies across clinical development, regulatory strategy, reimbursement, commercialization, financing, and international market expansion. The firm leverages relationships with physicians, hospitals, clinical research institutions, and industry experts to support product development and market access. The firm generally seeks active governance involvement following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is an Asia-based venture capital investor managing multiple USD-denominated funds backed by institutional investors, including academic and healthcare organizations. The firm invests across the full company development spectrum, from Seed through Pre-IPO, and maintains flexibility in investment stage and financing structure. The firm is particularly interested in opportunities with a meaningful connection to China, including companies with Asian founders, cross-border development strategies, or commercial potential in Asian markets.

The firm invests across therapeutics, AI-enabled drug discovery, diagnostics, medical imaging, and other technologies at the intersection of artificial intelligence and healthcare. Within therapeutics, the firm has a particular interest in novel modalities, including drug conjugates, radiopharmaceuticals, and cell and gene therapies. The firm is broadly indication-agnostic but prioritizes therapeutic areas with substantial market potential, including oncology, immunology, central nervous system disorders, pain management, and kidney diseases. The firm generally prefers therapeutic programs from IND-enabling development through clinical stages, although earlier opportunities may be considered beginning at the preclinical candidate selection stage.

From a company and management team perspective, the firm seeks differentiated technologies with strong scientific foundations, compelling commercial potential, and opportunities for cross-border growth. The firm places significant emphasis on management team quality and prefers leadership teams with relevant pharmaceutical or biotechnology industry experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a U.S.-based venture capital investor focused on deep-tech companies developing innovative technologies across healthcare, life sciences, and artificial intelligence. The firm manages multiple investment funds and is expanding its investment activities, with approximately 40% of its upcoming fund targeted toward healthcare and life sciences and the remaining 60% focused on AI and AI infrastructure. The firm invests globally, with a strong concentration of portfolio companies in the United States and a particular emphasis on connecting innovative companies with commercialization opportunities in Southeast Asia.

The firm invests across healthtech, medical technology, biotechnology, and deep-tech innovations with applications in healthcare and life sciences. The firm is broadly disease-agnostic and evaluates technologies addressing a wide range of healthcare challenges. Areas of interest include AI-enabled healthcare solutions, innovative medical technologies, biotechnology platforms, and technologies that improve clinical research, healthcare delivery, and operational efficiency. The firm is particularly interested in companies with technologies that can benefit from international clinical validation, regulatory development, and commercial expansion.

From a company and management team perspective, the firm does not impose specific requirements regarding management team composition or company structure. The firm differentiates its investment approach through hands-on operational and commercialization support, particularly for companies seeking expansion into Asian healthcare markets. Through its regional partnerships and healthcare innovation network, the firm can facilitate access to clinical research opportunities, healthcare systems, regulatory expertise, and commercialization resources. The firm also supports portfolio companies with market entry strategies, payer and reimbursement navigation, distribution partnerships, and broader business development initiatives.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.